---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-250757"
form_type: "8-K"
ticker: "NTLA"
cik: "0001652130"
company_name: "Intellia Therapeutics, Inc."
filed_at: "2025-10-27T23:59:59+00:00"
generated_at: "2026-05-17T02:11:27.242069+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Intellia pauses dosing in Phase 3 MAGNITUDE trials after Grade 4 liver event in one patient

## Summary
- Patient dosed on Sept 30, 2025, experienced Grade 4 liver transaminases and increased total bilirubin on Oct 24.
- Patient hospitalized and receiving medical intervention; Intellia consulting experts and regulators.
- Pause affects both MAGNITUDE (ATTR-CM, >650 enrolled) and MAGNITUDE-2 (ATTR-PN, 47 enrolled) trials.
- Over 450 patients estimated to have been dosed with nex-z across both trials to date.
- Conference call scheduled at 8:30 a.m. ET today to discuss the update.

## SEC filing metadata
- accession: 0001193125-25-250757
- form_type: 8-K
- ticker: NTLA
- cik: 0001652130
- company_name: Intellia Therapeutics, Inc.
- filed_at: 2025-10-27T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1652130/000119312525250757/0001193125-25-250757-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1652130/000119312525250757/d44351d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-250757
- JSON: https://secwatch.observer/filing/0001193125-25-250757.json
- Plain text: https://secwatch.observer/filing/0001193125-25-250757.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.